MARKET

PRRUF

PRRUF

Immutep Ltd
OTCPK
0.319
NaN%
Closed 09:30 02/12 EST
OPEN
--
PREV CLOSE
0.319
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.334
52 WEEK LOW
0.221
MARKET CAP
469.67M
P/E (TTM)
-11.5054
1D
5D
1M
3M
1Y
5Y
1D
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
Barchart · 6d ago
Immutep Hits 50% Enrolment Milestone in Global Phase III Lung Cancer Trial
TipRanks · 02/05 21:49
Analysts Are Bullish on Top Healthcare Stocks: Immutep Ltd (PRRUF), GeneDx Holdings (WGS)
TipRanks · 02/01 23:10
Immutep reports Q2 cash receipts from customers A$4,000
TipRanks · 01/29 13:21
Immutep Secures Dr. Reddy’s Partnership and Strengthens Clinical, Financial Position
TipRanks · 01/29 03:28
Immutep announces update on IMP761 from Phase I study
TipRanks · 12/22/2025 13:15
Immutep Reports Promising Phase I Data for First-in-Class Autoimmune Antibody IMP761
TipRanks · 12/21/2025 22:08
Ord Minnett Sticks to Its Buy Rating for Immutep Ltd (PRRUF)
TipRanks · 12/18/2025 00:35
More
About PRRUF
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.

Webull offers Immutep Ltd stock information, including OTCPK: PRRUF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRRUF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRRUF stock methods without spending real money on the virtual paper trading platform.